PsyRx in 2025: The Shell Was Cleaned Up, but the Real Test Is Financing the First Human Trial

Company Overview

PsyRx is not yet a biotech that should be read through sales, commercialization agreements, or product adoption. At the end of 2025 it was still a very small public company, with a market value of about NIS 12.4 million as of April 3, 2026, rebuilt around one development program: combining ibogaine with SSRI drugs for treatment-resistant depression. What is working today is not a commercial engine. It is a narrower mix of three things: the cleanup of the old business, a preclinical package that can be shown to regulators, and some ability to buy time through the capital markets.

That matters because a quick read of 2025 can go wrong in two opposite ways. The first mistake is to read the company as if it collapsed, because the annual loss was NIS 9.5 million. The second mistake is to read it as if the reset is already complete, because year-end cash rose to NIS 1.51 million, equity turned positive again, and the old business was sold. Both readings are incomplete. Most of the loss came from merger, listing, and anti-dilution accounting mechanics rather than from a blowout in operating cash burn. But the reassuring reading is also wrong, because the auditors still included a going-concern emphasis and the company itself states that the cash available at year-end and at the report date was not enough for 12 months.

What is actually holding up the story now? The company completed a preclinical safety study, ran an animal efficacy study, says it completed an ibogaine manufacturing process, and built a risk-management and regulatory-compliance plan. In addition, during October 2025 it entered into an agreement with a US supplier for an order of GMP-grade ibogaine HCL produced in Italy in a quantity of about 10 grams, and at the same time held a license to import and hold 15 grams of ibogaine at 98% purity as part of its preparation for a clinical trial in Israel. Those are not commercialization facts, but they do show that the company is no longer just a scientific idea on a slide deck.

What is still not clean is almost everything at the public-company layer. PsyRx has no revenue, no customers, no backlog, and no marketing or distribution setup. At the end of 2025 it had just 6 employees and service providers, rising to 7 near the report date. That is a structure suited to a very early development-stage company, not to one moving quickly toward a clinical finish line. The intellectual-property layer is also earlier than the headline suggests. The company has one relevant patent family around ibogaine and depression, but it explicitly says the broad patent application was filed without supporting experimental results and that broad, meaningful protection would require much more work, including human studies.

If the early investor filter has to be reduced to one sentence, it is this: PsyRx is currently a partially financed clinical option, not a proven medical business. What makes the story interesting is that the old shell is mostly gone, operating spend is still relatively low, and the company did build a real starting package for a first-in-human trial. What blocks a cleaner thesis is that the next financing round will likely determine not just whether the company reaches that trial, but how much value remains at the public-shareholder layer when it gets there.

The economic map at the end of 2025 looks like this:

This chart is a good starting point because it captures the 2025 paradox. Core spend actually fell, yet the reported loss jumped. Anyone who reads only the bottom line will miss what really happened, and anyone who strips out every one-off item may miss the second problem, which is that there is still no clean financing path to first-in-human data.

Events and Triggers

The merger solved one problem, but created a new layer of noise

The first trigger: the merger completed on November 27, 2025 fundamentally changed how the company should be read. Before the merger the public shell was still tied to cannabis-related activity, manufacturing, and sales. After the merger it stopped operating in that field and shifted to prescription-drug development through PsyRx. From an accounting standpoint the deal was treated as a reverse acquisition because PsyRx shareholders took control of the public company.

That has a double effect. On one side, the old shell was cleaned up. On December 31, 2025 the company completed the sale of the remaining assets of Cannabotech’s previous activity for NIS 10,000, and the consideration was received in full. On the other side, that cleanup came with heavy accounting noise: the excess purchase consideration and transaction costs created NIS 5.567 million of listing expenses. That is the main reason the annual loss looks much harsher than the underlying operating burn.

The second trigger: the merger did not just remove old assets, it also created a new capital structure. Ahead of the merger PsyRx holders received 4,746,319 shares and 10,958,777 non-traded rights into shares, subject to milestones. That matters because the company is not entering 2026 with a blank slate. It is entering it with a potential equity overhang built around rights and options. In other words, the organizational reset happened together with a deeper dilution risk.

The third trigger: the management turnover was part of the same event. At completion the CEO and chairman changed, and most of the former board members left. That is not inherently positive or negative. It does, however, underline that end-2025 PsyRx is not simply an extension of Cannabotech. It is a largely new platform at almost every important layer.

What actually moved forward scientifically

The fourth trigger: in scientific terms, 2025 was not a human-data year. It was a preparation year. The company says it completed a preclinical safety study, an animal efficacy study, and an ibogaine manufacturing process. In the toxicology study in animals, which ran for 14 days, no deaths or side effects were reported, and the company presents that as a safety base for moving toward human studies. At the same time, the zebrafish efficacy study was explicitly described as a pilot without a sufficient sample for statistical significance, and the company says it may repeat it later or move to another model.

The interesting point is that the company is not presenting itself as if the science debate is already behind it. The opposite is true. It is trying to move from early laboratory proof into a regulatory track. It also states that after the clinical study it intends to seek a Pre-IND meeting with the FDA, and only after a phase 2 study in humans does it plan to look for a large strategic partner for collaboration, funding, or regulatory leadership. That order matters: first a human trial, then a regulatory path, and only later a large partner.

The fifth trigger: the supply chain is still incomplete, but it now exists in an early form. On one hand, the company entered into an arrangement with a US supplier for GMP-grade raw material produced in Italy. On the other, it explicitly says ibogaine HCL may depend on a single supplier or a small number of suppliers, and that importing the material requires a Health Ministry license. So this is a step forward, but not a solved bottleneck.

The post-balance-sheet package is both a lifeline and a dilution layer

The sixth trigger: after the balance sheet date, on February 9, 2026, the company signed an investment agreement with a group of investors for NIS 3.5 million, and in March it added a second investment of NIS 1.65 million. Together that is NIS 5.15 million of potential cash before option exercises. If all the allocated options are exercised, the company would receive another NIS 7.111 million. At the near-term survival level, this is a critical event.

But it is not clean money. All the securities allocated under the investment and the additional investment would represent about 27.09% of the issued and paid-up capital on an undiluted basis, and 28.96% on a fully diluted basis. In addition, the package includes a ratchet on the allocated shares, restrictions on future capital raises above a certain ceiling, limits on taking debt or pledging assets without Grupman’s consent, and a right of first refusal in private placements until a future measurement date. If the shareholders’ meeting approves the deal, the private placement would give Eliran Grupman and Roy Rubinenko a control bloc in the company.

That is a core point in the thesis. In a pre-revenue biotech, investors tend to look first at the science. In PsyRx, at least in the near term, the capital structure matters just as much. What will determine the quality of the story in 2026 is not only whether there is a trial, but who will own how much of the company when the first real data point arrives.

Efficiency, Profitability and Competition

PsyRx is currently a business with no revenue. That is not just a framing choice. The company explicitly says it has no revenue, no customers, no backlog, and cannot yet estimate when revenue may begin. So the right question in this section is not "what does profitability look like." The right question is what the company is actually burning, what changed in spending quality, and how operating expense differs from the reported loss.

Start with the basics. In 2025 R&D expense fell to NIS 1.36 million from NIS 1.813 million in 2024. General and administrative expense was almost unchanged at NIS 1.029 million versus NIS 1.03 million. That means core operating expense totaled just NIS 2.389 million. For a listed biotech, that is a relatively low figure, and it shows how small the operating structure still is.

But the more interesting question is whether the decline in R&D reflects better efficiency or simple capital scarcity. The R&D breakdown gives a less comfortable answer. Of the NIS 1.36 million total, only NIS 63 thousand was wages and related costs, NIS 423 thousand was research and experiment services, NIS 574 thousand was medical and psychiatric consulting, and NIS 289 thousand was share-based payment. In other words, the development engine still rests mostly on outsourced research, consultants, and equity incentives rather than on a broad in-house team. That is not necessarily wrong. It just means the company has not yet built a heavy clinical infrastructure, so any move into trial execution will require operating expansion, not just regulatory signatures.

The split between the two halves of the year helps sharpen the read further. In the first half of 2025 the loss was NIS 2.856 million. In the second half it jumped to NIS 6.647 million. But almost all of that jump came from the NIS 5.567 million listing expense booked in the second half. R&D actually fell from NIS 802 thousand in the first half to NIS 558 thousand in the second half, and G&A was nearly identical in both periods. So the real conclusion is not that the company lost control of its cost base. It is that the company has still not reached the stage where its spending reflects a full-speed clinical organization.

On competition, the company itself paints an interesting picture. The main direct peers it highlights are focused on psilocybin, LSD, ibogaine derivatives, or psychedelic treatments at higher doses, in some cases already at later clinical stages. PsyRx presents itself as one of the few trying a microdosed ibogaine plus SSRI combination. That could turn into real differentiation, but it needs to be read correctly. It is not proven differentiation yet. It is conceptual differentiation still waiting for first-in-human work.

The patent moat is also only partial. The company has two patent families, but it says the first one, focused on psilocybin and bowel disease, is not expected to move into the national phase. The second and more relevant family is aimed broadly at combining ibogaine or a derivative with one or more antidepressants. It is pending across most jurisdictions and has been granted in South Africa, but the report also makes clear that grant there is automatic and not based on substantive examination. More importantly, the company says the application was filed without supporting experimental results, and that broad, meaningful protection would require many more studies, including studies in humans.

The second yellow flag comes from the Yissum agreement. The company has an exclusive commercialization license over technology developed in that joint research, but the footnote states that no patent application had been filed for the research conducted with Yissum by the end of the project. So anyone looking for a sealed technological moat gets only a partial one for now: there is a license, there is a patent application elsewhere, but there is still no hard layer of proof or filing that fully locks the story down.

Cash Flow, Debt and Capital Structure

The right cash bridge here is all-in cash flexibility

To read PsyRx correctly, the better frame is all-in cash flexibility. This is not a mature business where it is useful to talk comfortably about normalized cash generation before discretionary uses. The key question here is how much cash remains after real uses, and where that cash came from.

On the positive side, cash rose from NIS 243 thousand at the start of 2025 to NIS 1.51 million at year-end. On the less comfortable side, that increase did not come from the business itself. Cash flow from operating activity was negative NIS 442 thousand. Investing activity was almost nonexistent. The increase in cash came from financing activity of NIS 1.709 million, including NIS 679 thousand from issuing shares and options, NIS 800 thousand of bridge borrowing that was repaid by year-end, and NIS 1.03 million that came from the merger itself.

Put simply, 2025 did not show that the business can fund itself. It showed that the company managed to buy time through the market, a short bridge loan, and cash imported through the merger.

This is not a heavy-debt story. It is a cost-of-equity story

Another easy mistake is to read PsyRx like a real-estate or industrial company facing debt pressure. That is not the setup here. At the end of 2025 current liabilities totaled only NIS 1.051 million, including NIS 246 thousand to suppliers and service providers and NIS 805 thousand of other payables. The non-current liability that existed at the end of 2024 around the share-issuance mechanism had disappeared by year-end 2025. So there is no classic debt wall in the year-end balance sheet.

That is why the problem is of a different kind: not refinancing risk, but dilutive capital. The company states explicitly that without equity raises, financing, or new investors, the resources available to it do not allow it to continue normal operations for at least 12 months from the date the financial statements were approved. That is a very sharp disclosure. It also explains why the auditors kept the going-concern emphasis even after equity turned positive again.

Positive equity does not solve the runway question

Equity of NIS 826 thousand and working capital of NIS 824 thousand are obviously better than a deficit. But in a pre-revenue biotech they are not an end state. They are only a sign that the company has stepped away from immediate collapse. If management intends to spend around NIS 2 million in the 12 months after the report, mainly on human clinical work and another animal efficacy study, then year-end cash alone is plainly not enough.

This is the heart of the story. The financing package signed after the balance sheet date is not meant to accelerate a strong company. It is first meant to close a continuity gap. Only if the company gets past that point does it make sense to ask whether the ibogaine and SSRI combination can create a real regulatory or commercial edge.

Outlook

Four non-obvious findings should lead the 2026 read:

Finding one: 2025 was not a commercialization year that slipped. It was a transition year from an old shell into a real development-stage biotech. That makes 2026 a proof year, not a breakout year.

Finding two: the accounting reset created a large paper loss, but it did not answer who will fund the road to first human data and on what terms.

Finding three: the patent and IP story may become valuable later, but today it is still not a substitute for first clinical evidence or regulatory clearance.

Finding four: even if the financing package closes, it may materially reshape control and value allocation. So 2026 cannot be read only through science. It also has to be read through capital structure.

2026 is a proof year

Management’s stated strategy is fairly straightforward: recruit personnel with clinical-trial and regulatory expertise, enter into agreements to acquire ibogaine, obtain the approvals needed for a human clinical study, complete the operational preparation for the study, and sign agreements with medical centers in Israel. Only after a phase 2 study in humans does the company intend to seek a large strategic partner. So the 2026 path is not about revenue, and not even yet about a strategic partnership. It is about moving from a preclinical frame into an initial clinical one.

The report also gives a rough cost marker: the company intends to invest about NIS 2 million over the 12 months after the report date, mainly in a human clinical study and an animal efficacy study. That number needs to be read carefully. It is not huge in biotech terms, but it is larger than the cash the company had at year-end. That is exactly why the post-balance-sheet financing is not a bonus. It is a threshold condition.

What must happen in the next 2-4 quarters

For the thesis to hold, four things need to happen in the near term:

1. The post-balance-sheet financing must actually close. A shareholder-meeting document and an accounting disclosure are not enough. The market will want approval, allocation, and actual cash received.
2. The first-in-human filing needs to move from intention to timetable. Talking about regulation is not enough. Investors will want to see approval, medical-center agreements, or at least hard milestones.
3. The supply chain needs to prove it is real rather than merely preliminary. One raw-material order and one holding license are a start, not a full trial platform.
4. The company needs to show that rising spending reflects genuine clinical buildout rather than another round of buying time through capital engineering.

What could change the market read

In the short term the market will probably focus on fewer variables than the broad narrative suggests. The first is deal structure: does the financing close, what happens with the ratchet, and does a control bloc emerge. The second is regulation: any real movement toward first-in-human work could matter more than the accounting lines in 2025. The third is whether the company can show that its therapeutic combination is progressing through measurable steps rather than through a broad story around psychedelics, depression, and patents.

This chart captures the core dilemma. If the full package closes and the options are exercised, PsyRx would have a meaningful financing bridge relative to its size. But the same chart also shows that the existing company is extremely small relative to the capital it needs and the securities it may have to issue to secure that capital.

Risks

The biggest risk is still financing, but not in the usual sense of immediate insolvency. The risk here is that the company may keep raising capital on terms that dilute existing holders before it reaches meaningful clinical proof. The ratchet, first-refusal rights, limitations on additional financings, and the possibility of a control bloc after the meeting all make this a risk that has to be measured not only by how much cash comes in, but by the price of that cash.

The second risk is regulatory and clinical. The company is still before its first human trial. It explicitly says that clinical development success is uncertain, that it is subject to strict Health Ministry and FDA oversight, and that delays in approvals could hurt the pace of progress. In ibogaine’s case this is not abstract. The company itself details safety risks, drug-interaction risks, and the fact that the substance is tightly regulated and may be classified as dangerous in a number of jurisdictions.

The third risk is moat risk. The main patent application is broad, but still unsupported by clinical data. The company says it will need to show clear synergistic value to improve the odds of obtaining broad protection. In addition, no patent application had been filed for the Yissum-related research by the end of that project. Anyone building the whole thesis on future exclusivity may find that the patent progresses more slowly than the clinic, or that the clinic progresses before the moat hardens.

The fourth risk is plain execution risk. The company wants to recruit regulatory and clinical personnel, secure raw materials, sign with medical centers, and move into a first trial, all from a structure of just 6 to 7 employees and service providers. That model fits budget discipline, but it also leaves little room for mistakes, delays, or dependence on suppliers and outside consultants.

Short Interest Read

The short data does not tell a strong bearish story here. Quite the opposite. In the latest short-interest snapshot, dated December 4, 2025, the short position was zero and short float stood at 0.00%. Even at the brief peak recorded in November 2025, short float only reached about 1.00% and SIR reached 1.62. Those are low levels and do not point to crowding or a meaningful squeeze setup.

Put differently, skepticism around PsyRx today is not being expressed primarily through the lending market. It is being expressed through the price of capital, the very small market value, and caution around dilution. That distinction matters. It means near-term pressure is more likely to come from deal structure and trial execution than from an aggressive short base.

---

Conclusion

PsyRx ended 2025 in a better position than where it started it: the old business was largely stripped away, the accounting loss is heavily distorted by one-off reset items, and the path toward a first human trial looks more tangible than it did before. But this is still not a clean story. The central bottleneck has shifted from corporate identity to financing, regulation, and dilution.

What will shape the market reaction in the short to medium term is not whether the company can tell a broad story around ibogaine. It is whether it can close the financing package, advance the trial filing, and do so without hollowing out too much of the public-shareholder layer on the way.

Current thesis: PsyRx is no longer a struggling cannabis shell, but it is still not a biotech that has passed the proof stage. At this point it is an early clinical option whose value will be shaped by financing terms almost as much as by scientific progress.

What changed: in 2025 the company cleaned out the old activity, moved into a new public structure, and ended the year with positive cash and positive equity. At the same time, the clinical roadmap became clearer, but the dilution and control layer also became heavier.

Counter-thesis: the market may be focusing too much on dilution and not enough on the fact that the company has built a real starting package for first-in-human work and already signed a meaningful bridge financing package after the balance sheet date.

What could change the market read: actual closing of the financing, real regulatory progress, and a clear timetable for the first human study. On the other side, any additional low-price raise or the activation of investor protection mechanics would quickly turn attention back to shareholder erosion.

Why this matters: in a pre-revenue biotech, whoever funds the road to the first real data point captures a large share of the future economics. That makes PsyRx’s capital question central, not peripheral.

What must happen next: over the next 2 to 4 quarters the company needs to close the financing, show genuine regulatory progress toward first-in-human work, and build an operating frame that shows the new money is buying clinical proof rather than just more time on the clock.